Lytgobi
Payments companies reported to CMS as associated with Lytgobi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lytgobi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lytgobi
These are the largest totals companies reported as associated with Lytgobi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Amit Mahipal | Rochester, MN | Medical Oncology | $15,387.67 |
| Lipika Goyal | Stanford, CA | Medical Oncology | $10,000.00 |
| Milind Javle | Houston, TX | Hematology & Oncology | $5,970.28 |
| Aman Opneja | Raleigh, NC | Hematology & Oncology | $2,585.25 |
| Sameek Roychowdhury | Columbus, OH | Medical Oncology | $2,460.28 |
| Chih-Yi Liao | Chicago, IL | Hematology & Oncology | $2,115.54 |
| Richard Kim | Tampa, FL | Hematology & Oncology | $2,070.28 |
| Jaffer Ajani | Houston, TX | Medical Oncology | $1,320.00 |
| Samuel Klempner | Los Angeles, CA | Hematology & Oncology | $1,320.00 |
| Edmund Kopetz | Houston, TX | Medical Oncology | $791.44 |
Prescribed Lytgobi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.